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Introduction
Relatively simple in its form and function, the mammary
gland nevertheless requires a complex interplay of both
intracellular and extracellular signals for its development
into a branched glandular structure. The extracellular
matrix (ECM) has long been recognized as providing mor-
phogenic signals during mammary gland branching mor-
phogenesis [1]. However, systematic studies to define the
precise mechanism(s) by which the ECM accomplishes its
role are lacking. The unanswered questions include: do
interstitial ECM and basement membrane (BM) act as
single entities or do their individual components have dis-
tinct effects? What ECM receptors are used to transmit
these signals, and how do ECM remodeling proteinases fit
into these morphogenic events? In this review, we briefly
summarize a vast amount of research that touches on
these areas. We mention several existing hypotheses, put
forth a few more, and suggest some possible future direc-
tions for the field.
A branched epithelial structure includes a network of
tubes that are integral to the function of a number of glan-
dular organs [2,3]. Lung [4], kidney [5], salivary gland
[6,7], and mammary gland [8,9] are examples of organs
that develop through branching morphogenesis. The latter
is unique among these organs in that the majority of its
branching is postembryonic. Extensive branching begins
in puberty in the female and ceases after expanding to the
outer limits of the mesenchymal fat pad. A number of
paracrine, juxtacrine, and autocrine factors are known to
affect mammary gland branching morphogenesis [10]. We
have summarized these factors in Table 1; however, a
detailed discussion of these factors is beyond the scope
of this review. Here, we focus primarily on the studies that
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Abstract
A considerable body of research indicates that mammary gland branching morphogenesis is
dependent, in part, on the extracellular matrix (ECM), ECM-receptors, such as integrins and other ECM
receptors, and ECM-degrading enzymes, including matrix metalloproteinases (MMPs) and their
inhibitors, tissue inhibitors of metalloproteinases (TIMPs). There is some evidence that these ECM
cues affect one or more of the following processes: cell survival, polarity, proliferation, differentiation,
adhesion, and migration. Both three-dimensional culture models and genetic manipulations of the
mouse mammary gland have been used to study the signaling pathways that affect these processes.
However, the precise mechanisms of ECM-directed mammary morphogenesis are not well
understood. Mammary morphogenesis involves epithelial ‘invasion’ of adipose tissue, a process akin to
invasion by breast cancer cells, although the former is a highly regulated developmental process. How
these morphogenic pathways are integrated in the normal gland and how they become dysregulated
and subverted in the progression of breast cancer also remain largely unanswered questions.
Keywords: branching morphogenesis; extracellular matrix (ECM); integrins; mammary gland; matrix
metalloproteinases (MMPs)/tissue inhibitors of MMPs (TIMPs)
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Table 1
In vivo murine mammary morphogens
Morphogen Branching* Mode of application Reference
Extracellular factors
Estrogen ↑ Administered [110]
Estrogen ↑ Slow-release pellet [111]
Anti-estrogen ↓ Slow-release pellet [112]
Progesterone ↓ Slow-release pellet [113]
Parathyroid-hormone-related peptide ↓ Homozygous deletion [114]
Parathyroid-hormone-related peptide ↓ Transgenic overexpression [115]
Parathyroid hormone ↓ Transgenic overexpression [115]
Corticosterone ↓ Administered [116]
Epidermal growth factor (EGF) ↑ Slow-release pellet [117]
TGF-β1 ↓ Slow-release pellet [118,119]
TGF-β2 ↓ Slow-release pellet [118]
TGF-β3 ↓ Slow-release pellet [118]
Insulin-like growth factor 1 ↓ Homozygous deletion [120]
Growth hormone ↑ Slow-release pellet [117]
Hepatocyte growth factor ↑ Transgenic overexpression [121]
Relaxin ↑ Systemically administered [122]
Amphiregulin ↑ Overexpressing transplants [123]
Amphiregulin ↑ Slow-release pellet [123]
Hereguln-α ↑ Slow-release pellet [124]
Heregulin-β ↑ Slow-release pellet [124]
Wnt-4 ↓ Homozygous deletion [125]
Wnt-4 ↑ Overexpressing transplants [126]
C-neu ↓ Transgenic overexpression [127]
Colony-stimulating factor ↓ Homozygous deletion [128]
Eotaxin ↓ Homozygous deletion [128]
MMP-3 (stromelysin-1) ↑ Transgenic overexpression [69,70]
TIMP-1 ↑ Transgenic antisense TIMP-1 [12]
TIMP-1 ↓ Slow-release pellet [12]
Receptors
EGF receptor (EGFR) ↓ Homozygous deletion [129]
Epidermal-growth-factor receptor ↑ Transgenic/dominant negative [130]
Estrogen receptor α ↓ Homozygous deletion [131]
Progesterone receptor A (PRA) ↑ Transgenic overexpression [132]
Progresterone receptor A/B ↓ Homozygous deletion [133]
Prolactin receptor ↓ Homozygous deletion [134]
TGF-β2 receptor ↑ Transgenic/dominant negative [135]
Intracellular factors
CCAAT/enhancer binding protein β ↓ Homozygous deletion [136,137]
Gelsolin ↓ Homozygous deletion [138]
Hox6C ↓ Homozygous deletion [139]
*↑, augmentation of branching; ↓, inhibition of branching. MMP, matrix metalloproteinase; TGF, transforming growth factor; TIMP, tissue inhibitor of
metalloproteinase.
3involve ECM, integrin and nonintegrin ECM receptors,
ECM-degrading proteinases, and proteinase inhibitors in
regulation of mouse mammary gland branching morpho-
genesis.
Branched structures are first seen in the mouse mammary
gland in late embryonic development [11]. Expansion of
the ductal tree within the fat pad occurs rapidly after 3 to
4 weeks of age, when ovarian hormones begin systemic
circulation, and ceases around 10 weeks of age [12].
During branching morphogenesis, primary ducts elongate,
driven by terminal end bud proliferation, and the tree ‘fans
out’ within the fat pad through a process of terminal end
bud bifurcation and lateral side branching. Given the com-
plexity of mammary gland morphogenesis, we recommend
that models used to study this process consider the fol-
lowing three criteria: the length of the duct [ductal exten-
sion], the bifurcation of leading or primary ducts [or a
measure of the number of primary ducts], and the number
of side branches formed independently of bifurcation
[lateral branching from existing ducts]. These distinctions
are necessary, because there is some evidence to indicate
that each of these processes is differentially regulated by
ECM molecules, ECM receptors, the ECM degrading/
inhibiting enzymes, and soluble branching morphogens.
After 10 weeks of age, alveolar differentiation/regression
is the predominant morphological event, under the influ-
ence of the estrous cycle [13–15]. During pregnancy,
more lateral branching occurs to provide a connection
between milk-producing alveoli and primary collecting
ducts [16]. In most aspects, human breast development
resembles mouse mammary gland development [17],
although there are some notable differences [18].
Mammary ducts consist of an epithelial layer intimately
associated with a single layer of myoepithelial cells at their
basal end. A sheath of BM encircles the duct, which in
turn is surrounded by an outer ring of fibrous interstitial
ECM surrounded by a loose connective tissue. Within the
ductal unit, myoepithelial cells are more intimately con-
nected to BM than are epithelial cells, a spatial arrange-
ment that changes during different stages of mammary
development and cancer [19,20]. During morphogenesis
of the gland, differences in the composition, size, and
most probably function of the BM can be found when
comparing terminal end buds to subtending ducts. For
instance, the BM of terminal end buds displays differences
in thickness, being thinner (104 nm) at the tip and becom-
ing extensively thicker (1.4 µm) along the flank of the termi-
nal end bud. Moreover, the BM at the tip of the terminal
end bud is rich in hyaluronic acid, which may mediate mor-
phogenesis [21]. The BM of the ducts, in contrast, is a
meshwork of collagen type IV, laminin 1, laminin 5, and
heparan sulfate proteoglycans; other constituents such as
entactin/nidogen, vitronectin, and fibronectin are also
present [22].
Early studies involving development of the mammary gland
in vivo showed that inhibition or augmentation of either
collagens or glycosaminoglycan deposition attenuates
branching [1,21,23]. These experiments indicated that
regulation of mammary gland branching morphogenesis in
vivo is dependent not only on the maintenance of specific
types of ECM but also on total amounts of ECM. There-
fore, the regulation of branching may be dictated by the
composition of the ECM components present, the quantity
of the components, and where they are situated within the
developing tree. For instance, growth-promoting, nonad-
hesive, and promigratory ECM components may be more
prominent at the front of terminal end buds, whereas ECM
with the opposite characteristics could be found around
stationary ducts (Fig. 1). However, this hypothesis may be
too simplistic, because several ECM components exhibit
both promoting and inhibitory characteristics, depending
on the model used or the cell line examined [22], and, as
we discuss later, ECM receptors and ECM-degrading pro-
teinases need to be integrated into any mechanism of
ECM-directed morphogenesis.
ECM-receptor control of branching
morphogenesis
Direct attachment of epithelial cells to ECM occurs
through basally located integrins [24,25] (Table 2) and
nonintegrin ECM receptors [26–29] (Table 3). Gene
knockout studies in mice where particular integrin subunit
has been deleted indicate that integrin heterodimers con-
taining α3, α6, or β4 integrin subunits are not required for
mammary branching morphogenesis [30], while α2 inte-
grin knockouts exhibit diminished branching [31]. In cul-
tures of human mammary epithelial cells, blocking
antibodies against α3 integrin enhance branching when
cells are cultured within collagen type I [32], while the
same antibody inhibits branching when cells are cultured
on top of laminin rich basement membrane gel (lrBM),
Matrigel (BD Biosciences, Bedford, MA) [33]. These two
studies indicate that one integrin may relay opposing mor-
phogenic signals depending on which ECM ligand is
present, and that branching assays in culture may not
coincide with in vivo findings. The α6β4 integrin, which is
expressed in myoepithelium in vivo and in most immortal-
ized breast cell lines, is another integrin that is necessary
for branching in culture [33] but not in vivo [34]. Several
studies have examined the function of β1 integrin during
mammary gland branching morphogenesis. In vivo, devel-
oping mammary glands confronting blocking antibodies
against the γ1 chain of laminin (a subunit of all laminins
except laminin 5 and a major ligand of β1 integrin subunit)
or function-perturbing β1 integrin antibodies show terminal
end bud regression, fewer terminal end buds, and
decreased ductal elongation, while blocking antibodies
against the α6 integrin subunit had no effect [35]. In con-
trast, transgenic mice expressing a dominant negative β1
integrin subunit under the control of the MMTV (mouse
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4mammary tumor virus) promoter do not exhibit altered
mammary gland branching morphogenesis, but instead
showed a reduction in alveolar differentiation and an
increase in alveolar apoptosis [35]. In cultures of collagen
type I, blocking β1 integrin function inhibits branching, as
does blocking α2 integrin function [32]. These conflictingβ1 integrin results may stem from differences in the nature
of the cell types or ECM that confront the β1 integrin anti-
body and the extent of its loss or overexpression. In vivo,
endogenous β1 integrin is found in several cell types,
including the cap cells of terminal end buds, myoepithelial
cells, and luminal epithelial cells [35]. To make the picture
even more confusing, conditional knockout of β1 integrin,
within the mammary gland, appears to have no obvious
phenotypic consequences for the development of the
mammary gland (William Muller, McGill University, per-
sonal communication). Integrin studies have indicated that
for normal ductal development to occur, ECM adherence
through specific integrin subunits is necessary; however,
de-adherence is also required for normal branching, since
antibodies against β1 integrin, which ‘anchors’ cells to
ECM, attenuate branching morphogenesis [36]. Factors
that determine integrin-binding characteristics are
complex and include subunit composition, integrin recog-
nition sequences within the ligands, the nature of the diva-
lent cation present, and the activation state (high
anchoring or low) of the integrin [37]. Finally, spatial distri-
bution of integrins within the developing ductal tree must
be considered and is an area that has not been fully
explored. It is likely that integrins, in a manner analogous
to the ECM components, are differentially localized or dif-
ferentially activated within a developing tree, where pro-
morphogenic integrins are found in areas of migration,
invasion, and de-adhesion and integrins with opposite
characteristics are found at the base of the branching
point or at the cleft of a bifurcating structure (see Fig. 1).
Nonintegrin ECM receptors have also been implicated in
mammary gland branching morphogenesis. Overexpress-
ing cell-surface β-1,4-glactosyltransferase (GalTase) in
mammary epithelium leads to inhibition of mammary gland
morphogenesis [38]. This receptor participates in both
cell–cell and cell–ECM interactions through recognition of
N-acetylglucosamine residues on glycosylated ligands. It
is likely that dystroglycan, another nonintegrin cell-surface
ECM receptor, plays a key role in mediating morphogenic
signals from laminin 1 for acinus formation in the mammary
gland [39]; it may also be involved in branching signals, as
is the case in lung, kidney, and salivary glands [40].
Several types of collagen can act as ligands capable of
activating the discoidin domain receptor 1 (DDR1) tyro-
sine kinase [41]. DDR1 is expressed on both epithelium
and myoepithelium, and DDR1-deficient mice have exces-
sive mammary collagen deposition, delayed ductal devel-
opment, enlarged terminal end buds, hyperproliferative
ducts, and incomplete lactational differentiation [42].
Galectin, another nonintegrin ECM receptor, may also
function during mammary gland branching morphogene-
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Figure 1
Proposed spatial organization of the extracellular matrix (ECM) and integrin function during mammary gland branching morphogenesis. The
composition of the ECM that surrounds developing ducts and the type of integrin that relays signals from the ECM would depend on the
morphogenic event. Areas requiring invasion and proliferation and low adhesion (TEBs [terminal end buds], side branching) would have a unique
ECM/integrin profile compared with areas that are dormant (primary ducts, noninvasive end buds). Unique signals in areas that may require stem or
progenitor cell differentiation may require specific ECM-integrin profiles, unlike other areas.
5sis, since it has been shown to regulate ureteric bud
branching in the kidney [43].
Relation between ECM-degrading proteinase
activity and branching morphogenesis
Pioneering experiments from the Wessels and Bernfield
laboratories showed that increased activity of ECM-
degrading proteinases, such as collagenase or
hyaluronidase, altered branching morphogenesis in kidney,
lung, salivary gland, and pancreas [44,45]. Subsequent
studies found that collagenase reduced bifurcation by
inhibiting the deposition of collagen type I fibrils in the
developing salivary gland [46], and that a collagenase
inhibitor increased bifurcation, presumably by increased
deposition of collagen type 1 fibrils at the cleft. However,
ECM-degrading proteinases could affect branching mor-
phogenesis at levels well beyond the physical conse-
quences of remodeling the ECM (Fig. 2). First, signaling
through cell-ECM receptors would be lost or modified
when ECM is altered through ECM-degrading proteinase
activity [47,48]. Second, neo-epitopes, cryptic in intact
ECM molecules, may be exposed after digestion of ECM,
to provide new morphogenic signals to surrounding cells
[49,50]. Third, factors capable of influencing morphogene-
sis, which are intimately sequestered by ECM, may now
be released after ECM remodeling [51–54]. Fourth,
cell–cell attachment molecules may be lost through prote-
olytic cleavage, thereby releasing cells for migration
[55–57] or mesenchymal transition [57]. Finally, shedding
of cell-surface receptors or bound factors by sheddases,
which are also capable of digesting ECM, may release
morphogens [58,59].
Branching morphogenesis, whether examined in the
mammary gland or in cell culture, involves an invasive
process. One class of ECM-degrading proteinases is the
matrix metalloproteinases (MMPs), many of which are
capable of facilitating cellular invasion [60–62]. Their activ-
ity has been shown to mediate lung [63–65], kidney
[34,66], and salivary gland [67] branching. In the mouse
mammary gland, MMP mRNA and activity are evident during
branching morphogenesis and involution [12,68–70]; and
in transgenic mice, overexpression of active MMP 3, MMP 7
(matrilysin), and MMP 14 (MT1-MMP; membrane type-1-
MMP) led to ductal hyperplasia and in the case of MMP 3
and MMP 14 also to tumorigenesis [69,70–73]. Although
limited branching analysis was performed in the MMP 7 and
MMP 14 transgenic mice, these studies suggest that
MMP 3 overexpression is associated with altered branching
morphogenesis, while overexpression of MMP 7 or MMP 14
is not. Determining the differences in substrate specificities
between MMPs should allow an understanding of why
certain MMPs, when overexpressed, exhibit morphogenic
capabilities while others do not. MMP 14 and MMP 2 are
key proteinases in branching morphogenesis during epider-
mal-growth-factor-mediated lung development [74], and
MMP 14, independent of pro-MMP 2 activation, can confer
invasion and tubulogenesis of noninvasive MDCK cells in
matrices of collagen type I, while MMPs 1, 2, 3, 7, 9, 11,
and 13 cannot [75]. Therefore, tissue specificity also
appears to determine whether specific MMPs can act as
branching morphogens.
Induction of MMP 3 in a clonal mouse mammary epithelial
cell line, ScP2 [76], leads to cleavage of E-cadherin, loss
of associated β-catenin, and epithelial-to-mesenchymal
transition (EMT), and to an invasive phenotype [57]. We
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Table 2
Integrin heterodimers and their corresponding ECM ligands
Integrin ECM ligands
α1β1 Laminins, collagens
α2β1 Laminins, collagens, tenascin
α3β1 Laminins, collagens, fibronectin, entactin
α4β1 Fibronectin, osteopontin
α5β1 Fibronectin, tenascin
α6β1 Laminins
α7β1 Laminins
α8β1 Fibronectin, tenascin, vitronectin
α9β1 Collagen type I, laminin, tenascin, osteopontin
αVβ1 Vitronectin, fibronectin, osteopontin
α2β1 Collagen type I
αIIbβ3 Fibronectin, vitronectin, thrombospondin
αVβ3 Vitronectin, fibronectin, osteopontin, entactin,
thrombospondin, denatured collagens, tenascin, laminin
α6β4 Laminins
αVβ5 Vitronectin, osteopontin, fibronectin
αVβ6 Fibronectin
αVβ7 Fibronectin
αVβ8 Fibronectin, vitronectin
Adapted from [140].
Table 3
Nonintegrins implicated in branching morphogenesis
Nonintegrin ECM ligands
β-1,4-glactosyltransferase N-acetylglucosamine residues
Dystroglycan Laminin 1
Discoidin domain receptor 1 Collagens
(DDR1)
Galectin Laminin, fibronectin, vitronectin,
N-acetylglucosamine residues
6have further shown that MMP 3 can induce branching
morphogenesis in mammary organoids in three-dimen-
sional cultures of collagen type I [77]. Importantly, MMP 3-
induced branching occurs in the absence of added
growth factors in these organoid cultures. It is tempting to
speculate that MMP 3 activity leads to a transient EMT
that may be necessary for the invasion of the mammary
gland ductal tree in the fat pad (Fig. 3). The idea is that at
the leading edge of ductal migration, epithelial cells may
exhibit mesenchymal-like characteristics allowing them to
invade as an organized structure, similar to what happens
in the development and patterning of several other tissues
and organs that exhibit EMT [78].
We have determined that the minimal requirements for
branching morphogenesis in clonal populations of
mammary epithelial cells are MMP 3 plus epimorphin, a
myoepithelial- and stromal-derived mammary morphogen
[79]. Indeed, epithelial cells that branch in culture without
requiring additional exogenous epimorphin are those that
already express epimorphin [80]. Increased expression of
epimorphin in mammary glands of transgenic mice leads
to enlarged ducts and increased alveoli, underscoring its
role in mammary gland morphogenesis [80]. We have
found that epimorphin-mediated branching occurs in part
through upregulation of MMPs, including MMP 3 [77].
These culture studies, along with the transgenic work
cited above, provide a role for MMP 3 and epimorphin as
two key morphogenic factors during mammary gland
branching morphogenesis.
The serine proteinases urokinase plasminogen activator
(UPA) and tissue plasminogen activator process plasmino-
gen into plasmin, which, in turn, is capable of degrading
ECM and activating MMPs [81]. Plasminogen, but not
UPA, has been shown to be necessary for normal
mammary development, as plasminogen-deficient mice
show a delay in early ductal development and a large per-
centage of them are unable to lactate because of a lack of
secretory epithelium [82]. In contrast, UPA-deficient mice
show no detectable mammary phenotype during develop-
ment or involution [82]. Other evidence suggests that the
plasma kallikrein may be the dominant plasminogen activa-
tor in the mammary gland [83]. We have shown that
MMPs can cooperate with the plasminogen/plasmin
system during mammary epithelial branching morphogene-
sis in a three-dimensional matrix of collagen type I. These
studies indicate that while UPA does not induce branch-
ing, plasmin can, but in an MMP-dependent manner [77].
In ongoing studies, a number of MMP-null mice are being
examined during mammary gland branching morphogene-
sis to distinguish those MMPs mediating branching elon-
gation versus those mediating lateral branching. These
results suggest that certain MMPs, such as MMP 2,
promote ductal elongation, whereas MMP 3 induces
lateral side branching (Wiseman et al., JCB in press).
Determining the precise function of each ECM-degrading
proteinase in branching morphogenesis is a time-consum-
ing task, given their localization, activation, and interplay as
well as their ever-increasing numbers. However, that pro-
Breast Cancer Research    Vol 6 No 1 Fata et al.
Figure 2
Mechanism by which matrix metalloproteinases (MMPs) can affect branching morphogenesis. 1. Proteolytic digestion of extracellular matrix (ECM)
would alter ECM-integrin tethering and ECM-integrin signalling [47,48]. 2. Cleavage of ECM may produce soluble ECM fragments containing
morphogenic activity [49,50,53,54]. 3. ECM-sequestered factors may be released to produce morphogenic gradients or signalling [52,54]. 4. Loss
of cell–cell adhesion molecules by MMPs would lead to epithelial-to-mesenchymal transition and increased invasiveness [55–57]. 5. Ligand or
receptor shedding might initiate autocrine, juxtacrine, or paracrine morphogenic signalling [58,59].
7teinases do play a role in mammary branching is clear.
There is more than one possible mechanism by which
MMPs can regulate mammary gland branching morpho-
genesis (see Fig. 2); it will therefore be an interesting chal-
lenge to tease out which molecular pathway or pathways
are involved for which proteinase during this developmen-
tal process. Focused research on the spatial distribution
of substrates within the mammary gland and localization of
MMP activities are likely to provide informative answers.
MMP proteinase inhibitors in branching
morphogenesis 
If ECM-degrading enzymes are involved in branching mor-
phogenesis, one would then predict that their biological
inhibitors should antagonize the process. While this is
generally the case, the results are not always as predicted.
For instance, upregulation of tissue inhibitor of metallopro-
teinase (TIMP)-1 increases bifurcation in the salivary gland
[46] and induces higher numbers of branches in lung
development [84], while in the mammary gland, upregula-
tion of TIMP-1 leads to inhibition of ductal elongation
without affecting bifurcation or higher-order branching
[12]. In kidney development, TIMP-2 downregulation
through antisense oligonucleotides increases ureteric
branching morphogenesis [85], and, similarly, transgenic
antisense expression of TIMP-1 leads to supernumerary
branches associated with increased ductal elongation and
increased mammary epithelial proliferation [12]. Therefore,
the function of TIMPs, similar to that of MMPs, needs to be
put in the context of tissue-specific microenvironments
during branching morphogenesis [86]. It is likely that the
processes of bifurcation and ductal extension, both char-
acteristics of branching morphogenesis, are differentially
regulated by TIMPs. That is, TIMP upregulation may
increase bifurcation through increased focal deposition of
ECM molecules, while concomitantly it may hinder ductal
extension through limiting degradation of physically con-
straining ECM.
Downmodulation of TIMP-1 by transgenic antisense
expression in the mammary gland leads to increased
branching and is associated with a loss of laminin in the
ductal BM but not collagen type IV, suggesting that
laminin degradation may provide a morphogenic signal
[12]. Cleavage of laminin 5 by MMP 2 (gelatinase A) and
MMP 14 produces a laminin fragment capable of inducing
mammary epithelial invasion [50,87]. However, whereas
antisense downregulation of TIMP-1 augments branching
morphogenesis, an analysis of TIMP-1-null mice indicates
that mammary gland branching morphogenesis is not
overtly affected (Fata and Khokha, unpublished findings,
and Wiseman et al., JCB in press). It remains to be seen if
compensatory upregulation of other TIMPs are occurring
in these animals.
Given the multiplicity of MMP substrates, TIMPs should be
viewed as molecules that mediate both ECM-dependent
and ECM-independent events. TIMP-1 and TIMP-2 have
been shown to stimulate growth of cells in culture, includ-
ing breast cancer cells [88,89]. TIMP-2 mediates activa-
tion of MMP 2 on the cell surface through formation of a
ternary complex with MMP 14 [90]. One could speculate
that expression of TIMP-2 leads to an increase in the acti-
vation of MMP 2 on the cell surface by MMP 14, thereby
localizing proteinase activity to the immediate extracellular
space to augment branching. In MDCK cells, MMP 14
plays a pivotal role in invasion and branching morphogene-
sis in collagen-type-I matrix [91]. TIMP-3 has a unique
ability to inhibit several cell-surface sheddases called
ADAMs (a disintegrin and a metalloproteinase), including
tumor-necrosis-factor-α-converting enzyme (TACE; [92]),
and so far is the only TIMP that becomes tightly bound to
ECM after secretion [93]. TIMP-3-deficient mice show
accelerated mammary involution and increased rates of
adipogenesis [94]. The latter phenotype could be
expected from evidence that indicates ADAMs contribute
to adipogenesis [95]. Intriguingly, TACE-deficient
mammary glands have a severe growth and branching
phenotype (M Sternlicht, S Wohler Sunnarborg, DC Lee
and Z Werb, unpublished observation). It is possible that
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Figure 3
Proposed morphogenic mechanisms mediated by matrix
metalloproteinases (MMPs) and MMP inhibitors. At sites of invasion
and migration (TEBs [terminal end buds], lateral side branches,
invasive end buds), MMP activity may induce a transient epithelial-to-
mesenchymal transition (EMT), thereby allowing the tip to move
forward. Alternatively, high levels of MMP inhibitors may force an
‘ameboid-like’ movement, independent of MMP activity, through the
meshwork of the extracellular matrix [96].
8TIMPs could force mammary epithelial cells into an MMP-
independent migration under some conditions (see Fig. 3).
Recent results indicate that inhibition of metalloproteinases
does not impede MDA-MB-231 mammary carcinoma cell
migration through a collagen matrix, and the cells continue
to move using an ameboid migration [96]. Whether or not
this is a compensatory mechanism or whether these cells
do not use MMPs at all remains to be determined.
Conclusion: to branch or not to branch
During expansion of the ductal tree into the fat pad, there
is continuous turnover of both BM and stromal ECM
[12,21,97]. We now know that this degradation is not only
to remove an impediment to migration, but that it is also a
process in which morphoregulatory signals are generated
and/or quenched through remodeling. Remodeling and/or
dissolution of impeding ECM would facilitate forward pro-
gression of a ductal branch and lessen adhesion of cells
to their substrata. Improper remodeling of ECM in the
mammary gland can lead to altered branching, as seen
with hyaluronidase treatment [21], cis-hydroxyproline treat-
ment [1], and changes in the proteinase/proteinase
inhibitor balance [12,69,70].
Understanding how ECM imparts morphoregulatory
signals to breast epithelium is of importance also in car-
cinogenesis. Breast carcinoma most often is associated
with an extensive ‘stromal reaction’ termed desmoplasia,
in which excess collagen is deposited. In fact, changes in
the integrity, deposition, and/or composition of the ECM
are often associated with breast cancer [22,98]. More-
over, upregulation of expression of the fibrillar collagen
gene is a robust indicator of metastatic phenotype
[99–101]. ECM and factors that attenuate or augment
signaling regulate branching morphogenesis in a process
that may be thought of as controlled invasion. Where ECM
accumulates aberrantly, as is the case for collagen type I
in desmoplasia and fibrosis, other processes also begin to
go wrong. For example, increased collagen type I has
been shown to upregulate activated MMP 2 in human
metastatic breast cancer cells [102]. This in turn could
increase production of the morphogenic fragment of
laminin 5, enhancing an already promigratory environment.
Other collagens such as types III, V, and VII are also
altered in expression and deposition in breast cancer
[64,103–105], undoubtedly imparting signals that lead to
loss of structure and function in the breast.
Laminin 1 has been shown to be produced by myoepithe-
lial cells in the breast [20] and is downregulated in breast
carcinoma together with the hemidesmosome integrin
subunit α6 [106]. Downregulation of laminin 1 and α6 inte-
grin is most likely due to the absence of the normal
myoepithelial cells or the presence of aberrant breast
cancer myoepithelial cells [20]. Other ECM proteins such
as fibronectin, tenascin, thrombospondin, and gly-
cosaminoglycans also change in breast cancer [22].
Other hallmarks of breast cancer include altered expres-
sion of ECM-degrading proteinases and their inhibitors
[107] as well as loss or aberrant expression of ECM
receptors [108,109]. How different components of the
cell–ECM signaling pathways contribute to the disease
state is far from clear. What we do know is that prolifera-
tion, migration, and adhesion — all fundamental processes
of morphogenesis — are profoundly affected.
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